Recombinant Human Endostatin Market 2023 : Endostatin is a naturally occurring, 20-kDa C-terminal fragment derived from type XVIII collagen. Human monomeric endostatin is a globular protein containing two disulfide bonds: Cys162−302 and Cys264−294.

Report Overview

Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.

The USA market for Recombinant Human Endostatin is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The China market for Recombinant Human Endostatin is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The Europe market for Recombinant Human Endostatin is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.

The global key manufacturers of Recombinant Human Endostatin include Thermo Fisher Scientific and PeproTech etc. In 2021, the global top five players had a share approximately % in terms of revenue.

Top Key Players:

  • Thermo Fisher Scientific
  • PeproTech

Recombinant Human Endostatin Market By Applications

  • Medical Care
  • Scientific Research
  • Others

Recombinant Human Endostatin Market By Types

  • Purity:95%
  • Others

Get a Sample PDF of report –https://www.360researchreports.com/enquiry/request-sample/21623021

For More:

Thick-Film Hybrid Integrated Circuits Market

Dark Circle Eye Cream Market

String Lights Market

Antenna in Package (AiP) Market

Adhesives and Sealants Market